Qualia Bio, LLC, a Los Angeles based specialty healthcare consulting firm announced today that it has been acquired by BluePath Solutions.

Qualia Bio’s business focus is on healthcare policy, market access, and reimbursement. Qualia Bio assists clients in the assessment and management of market access risk through a mix of data analytics, custom consulting research, and syndicated reports which deliver actionable insights to help biopharmaceutical manufacturers optimize brand access.

BluePath provides market-leading solutions in the areas of value marketing & communications, health economic modeling, and health economics and outcomes research. The services and products provided by Qualia Bio are complementary to BluePath’s existing services and allow the firm to provide a more comprehensive set of offerings to further support its clients.

“A data renaissance is happening in biotech, particularly with changing legislation and major biotech innovation” said Sophie Snyder, Managing Director of Qualia Bio. “With BluePath’s experienced team and leadership, I know we will be able to deliver on our vision of applying data to provide valuable insights, drive strategic decision-making, and influence policy. I am excited about the opportunities for our current employees and the new colleagues that we get to work with to deliver innovative tools and methods to biotech manufacturers.”

“We are excited to announce the acquisition of our firm by BluePath Solutions” said Brian Duffant, a Founding Partner at Qualia Bio. “As scientific advances have led to a shift in therapies from lower cost brands which treat broad populations to more effective and costly targeted agents for smaller patient populations, the need to establish and communicate brand value has changed markedly. “With access to BluePath’s resources and expertise, we are better able to serve clients with more comprehensive offerings to help them establish brand value and differentiation.”

“We are pleased to welcome Qualia Bio to BluePath and look forward to the expanded expertise and enhanced capabilities this transaction brings to our clients” said Matthew Gitlin, PharmD, Founder and Managing Director of BluePath. Gitlin added, “Our newly combined firm will aid clients in effectively and efficiently communicating the unique value of their brands to healthcare decision makers and help patients gain access to innovative new therapies.”

About Qualia Bio

Qualia Bio is a specialty healthcare consulting firm. We are focused on healthcare policy, market access, and reimbursement issues as they relate to the biopharmaceutical industry.

We help our life science clients assess and manage market access risk through the use of quantitative and qualitative analytics. Our insights aid clients in anticipating and responding to emerging market developments and long-term industry trends.

BluePath Solutions is a consulting firm specializing in health economics and value communications. BluePath helps clients in the biopharmaceutical, medical device, and medical diagnostic space to attain, maximize, and retain the value of their healthcare technologies — not just at one static point in time, but across the entire lifecycle of the technology.

For additional information related to this transaction, please contact BluePath at info@bluepathsolutions.com or visit the company website at www.bluepathsolutions.com.